This Pharma Giant Is Using AI to Dominate Drug Discovery
There’s no denying modern-day artificial intelligence (AI) is doing some pretty cool stuff. But, to say it’s been…
New peptide drugs on the horizon with PepLib–Lilly collab
New global partnership aims to turn PepLib’s peptide tech into therapies that could reshape treatment and longevity. Think…
What’s the Better Long-Term Investment?
Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY) are rivals in the GLP-1 drug market and are…
Hims and Hers Health’s compounded Wegovy pill offering fuels market jitters
Feb 5 (Reuters) – Hims & Hers said it would begin offering compounded versions of Novo Nordisk’s Wegovy…
Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026
Eli Lilly’s (NYSE: LLY) share price jumped 39% in 2025, driven by investors eager to benefit from the…
Novo Nordisk shares plunge on outlook warning as Mounjaro rival races ahead
Weight loss drug maker Novo Nordisk has seen shares slump after warning over a sales plunge amid price…
My Top AI Healthcare Stock to Buy and Hold for 20 Years
Eli Lilly has made several moves to boost its artificial intelligence (AI) capacity. It could help complement its…
How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q4 Results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…
Eli Lilly Soared by 39% in 2025, but Here’s Another Healthcare Stock to Buy in 2026
Eli Lilly (NYSE: LLY) delivered a gain worthy of a technology growth stock last year. The pharma giant’s…
Takeaways on turmoil surrounding FDA fast-track drug program
WASHINGTON (AP) — A plan to slash drug review times at the Food and Drug Administration is sparking…
FDA commissioner’s drug review plan sparks alarm
WASHINGTON (AP) — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored…
From OpenAI’s offices to a deal with Eli Lilly — how Chai Discovery became one of the flashiest names in AI drug development
Drug discovery, the art of identifying new molecules to develop pharmaceuticals, is a notoriously time-consuming and difficult process.…